Jason Scott Slakter, Chief Executive Officer at Ohr Pharmaceutical Inc (OHRP), bought 3,000 shares at $4.12 ($12K) on 2015-12-07, disclosed to the SEC on 2015-12-08.
Scheduled purchase ($12k) by Chief Executive Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $4.00 | 200 | $800 | 6.5% |
| 2 | $4.02 | 800 | $3K | 26.3% |
| 3 | $4.05 | 300 | $1K | 9.9% |
| 4 | $4.07 | 300 | $1K | 10.0% |
| 5 | $4.10 | 100 | $410 | 3.4% |
| 6 | $4.12 | 1,200 |
| $5K |
| 40.5% |
| 7 | $4.13 | 100 | $413 | 3.4% |
| Total | $4.07 avg | 3,000 | $12K | 100% |
| Filing → |
| OHRP | BUY | 2016-05-26 | $11K | — | Filing → |
| OHRP | BUY | 2016-05-25 | $89K | — | Filing → |
| OHRP | BUY | 2016-04-12 | $21K | — | Filing → |